G protein-coupled receptor 183 (GPR183/EBI2) is one of the key regulators of the innate immune system, and it has been shown to be upregulated in multiple sclerosis (MS) plaques. In a recently reported study, researchers from Medical University of Gdansk evaluated the effects of pharmacological modulation of GPR183 signaling on remyelination.